Produced by 
APR 25, 2017 10:00 AM PDT
WEBINAR: Discover Potentially Predictive Immuno-Oncology Biomarkers using Next-Gen Sequencing
SPONSORED BY: Thermo Fisher Scientific Ion Torrent
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
6 31 5281

Speakers:
  • Director of Bioinformatics R&D, Thermo Fisher Scientific
    Biography
      Fiona Hyland is Director of Informatics R&D at Thermo Fisher Scientific. Fiona majored in Genetics as an undergraduate in Trinity College, Dublin, and in Quantitative Genetics (with minors in Statistics and Population Genetics) as a graduate student at Cornell University. Fiona then worked in information technology for several years (in web development, at an internet start-up, and at Nortel Networks), before returning to Biotech, joining Applied Biosystems (subsequently Life Technologies, now Thermo Fisher Scientific).

      For Ion Torrent, Fiona's teams launched tools to help interpret sequencing data in clinical research contexts, including algorithms for tumor-normal analysis, genetic disease, CNV and aneuploidy detection, gene fusion, and genetic annotation.

      Fiona has authored many scientific articles, conference presentations, and patents, has been a reviewer for a range of scientific journals, has been a member of the 1000 Genomes consortium, and the CDC Nex-StoCT II Informatics Consortium and the FDA SEQC Consortium, and has presented widely at scientific conferences.
    • Professor of Pathology at Roswell Park Cancer Institute; President of OmniSeq Precision Medicine Technology
      Biography
        Dr. Morrison is the President, Chief Scientific Officer and Founder of OmniSeq Precision Medicine Technology. He developed the vision for OmniSeq while leading the Center for Personalized Medicine and Division of Molecular Pathology at Roswell Park Cancer Institute.

        Dr. Morrison remains a Professor and program member in Cancer Genetics at Roswell Park Cancer Institute. He was recently awarded the Thomas B. Thomasi Hope Award. This Award is the highest honor Roswell Park bestows to the faculty member whose work has made significant advances in the fight against cancer while brining hope to cancer patients.

        Recognized nationally for his work in translational medicine, Dr. Morrison has authored or co-authored more than 100 peer-reviewed manuscripts with a focus on molecular pathology. His work has been published in leading journals including Nature, Journal of Clinical Oncology and Cancer Research. He recently published a leading work in next generation sequencing of bladder cancer in PNAS.

        Dr. Morrison is a member of the College of American Pathologists and Association of Molecular Pathology. As a board-certified pathologist, Dr. Morrison has led the development of OmniSeq Comprehensive - a next generation sequencing technology that focuses on DNA-Seq and RNA-Seq to increase throughput with increased accuracy, identifying therapeutically actionable variants in cancer patients.

        Dr. Morrison received his Doctorate in Veterinary Medicine from the Ohio State University College of Veterinary Medicine followed by his Doctorate in Medicine from the University of Kentucky. He completed his residency at the Ohio State University Medical Center.

      Abstract:

      DATE: April 25, 2017
      TIME: 10:00am PT, 1:00pm ET

      Immunotherapy has emerged as one of the most promising options for the future treatment of a growing number of cancers and is touted to be the next revolution in our fight against this complex disease. One of the most effective modalities of treatment, thus far, has been in the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors.

      Current biomarkers and immunohistochemistry (IHC) assays are not accurate predictors of which individuals are most likely to respond or benefit from immunotherapeutic agents, thus prompting the need to identify better biomarkers that can guide therapy selection in the future. 

      Next-generation sequencing (NGS) offers clinical researchers a cost-efficient and rapid way of analyzing multiple targets simultaneously from as little as 10ng of total RNA isolated from formalin-fixed, paraffin-embedded (FFPE) samples.  

      In this webinar, our speakers will show how Thermo Fisher Scientific’s Oncomine Immune Response Research Assay enables the interrogation of gene targets that are critical for research into immune response.
       
      Topics to be covered:

      • Fiona Hyland will describe how the content for a new gene expression NGS-based assay was carefully selected and will compare its performance against other assay(s) available on the market.
      • Dr. Carl Morrison will describe a verification study for establishing the performance of the new Oncomine Immune Response Research Assay in a clinical research lab.

      Key learning objectives for attendees:

      • How to improve immuno-oncology biomarker discovery using NGS
      • Benefits of applying a targeted gene-expression based approach for studying the tumor microenvironment
      • How to implement the Oncomine Immune Response Research Assay in a clinical research lab 

      Who should attend:

      • Scientists involved in biomarker discovery and drug development 
      • Contract Research Organizations focused on oncology services
      • Immunology and oncology translational/clinical research laboratories interested in adopting NGS


      For Research Use Only. Not for use in diagnostic procedures.


      Show Resources
      Show Resources
      Connect with us